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ABSTRACT
OBJECTIVE: The objective of this selective EBM is to determine whether or not, “Are the use
of antibiotics an effective treatment for relieving symptoms of depression in adults?”
STUDY DESIGN: Review of three English language primary studies, published between 20102016.
DATA SOURCES: Three randomized controlled trials (RCTs) were found using PubMedNCBI. These studies analyzed the effectiveness of probiotics in adults with symptoms of
depression.
OUTCOME MEASURED: The main outcome measured was improvement of symptoms of
depression after the administration of probiotic supplements. Outcomes were assessed using data
from self-reported questionnaires, which include the Hopkins Symptom Checklist (HSCL-90),
Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), and the
Leiden Index of Depression Sensitivity Scale (LEIDS-r). P-values were used to assess the
significance of outcomes.
RESULTS: All three studies showed improvement in depressive symptoms with probiotic
supplementation. There were significant decreases in depression scores during post-intervention
evaluations when compared to pre-assessment data. Differences between probiotic and placebo
groups were found to be statistically significant in two out of the three studies. Overall, study
participants who were given probiotics had lower depression scores than those who were given
the placebo, after probiotic supplementation.
CONCLUSION: The results of the RCTs support probiotics as an effective treatment for
relieving symptoms of depression in adults. The possibility of probiotic use in depression offers
a safer and more affordable option in comparison to currently available therapies.
KEY WORDS: Probiotics, Depression.
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INTRODUCTION
Major depressive disorder is a complex mental condition that consist of mood, physical
and cognitive symptoms that can cause significant distress or impairment in social, occupational,
and in other important areas of function.1 Depression can result from biological factors such as
familial gene variants and can also be social in nature due to developmental problems and
adverse life events. Symptoms vary widely but most frequently include anhedonia, withdrawal
from activities, and feelings of guilt. Also included are inability to concentrate, some cognitive
dysfunction, anxiety, chronic fatigue, feelings of worthlessness, somatic complaints, loss of
sexual drive, and thoughts of death.2 To medically diagnose depression, five or more of the
above symptoms have to be present including either depressed mood and anhedonia for 2 weeks
and result in impaired social, occupational, or other areas of functioning.1 Depression can be a
secondary response to a primary medical condition or the psychological effect of medications,
therefore these are exclusionary criteria for diagnosis.
Depression is the most common mental disorder in the United States with an estimated
16.1 million adults having at least one major depressive episode in 2016.3 Depression is also the
leading cause of disability among people ages 15-44, resulting in almost 400 million disability
days per year, substantially more than most other physical and metal conditions.4 Depression is
associated with higher rates of disease and has a major risk of mortality from suicide.5 Patients
who are depressed with comorbid conditions are at higher risk for hospitalization, tend to have
longer hospital stays, and have worst outcomes than their non-depressed counterparts.2 The
economic burden of depression, including workplace costs, direct costs and suicide related costs
was estimated to be $210.5 billion in 2010.4 Depression is listed among the twenty leading
principal reasons for outpatient office visits, and it is estimated that 30% of primary care patients
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have depressive symptoms.2 According to the Center of Disease Control and Prevention (CDC),
the percentage of physician visits with depression indicated on the medical record was 10.3% in
2014 and out of all chronic conditions seen in the emergency room, depression made up 8.3% of
total visits in that same year.6
There is an established link between mood disorders and gastrointestinal functioning. It is
known that stress can trigger or exacerbate conditions such as inflammatory bowel and peptic
ulcer disease. Evidence of this link is shown with the successful use of antidepressant therapies
in the treatment of inflammatory bowel disease and other gastrointestinal disturbances.7 This
leads to questioning of the reverse, “Can variations in gastrointestinal functioning impact mood
disorders?” Recent studies suggest that gut microbiome play a role in the functioning of the
nervous system through the hypothalamic pituitary-adrenal axis and that bacteria can change
central nervous system molecules implicated in the pathophysiology of depression.8 If this is
found to be true, treatment modalities utilizing the effects of probiotics have the potential for
success in treating depressive symptoms.
Methods currently used to treat depression include psychotherapy, antidepressants, and
electroconvulsive therapy (ECT). Milder forms of the disease can be treated with nonpharmacological means as simple as engaging in relaxation exercises. A combination of
psychotherapy and antidepressants is recommended in the treatment of depression.2 However,
psychotherapy is not always affordable and antidepressant medications have many adverse side
effects. Probiotic therapy is being proposed as a possible treatment option for depression because
they lack the adverse side effects of antidepressants and are currently readily available to patients
at a much lower cost than psychotherapy.
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OBJECTIVE
The objective of this selective EBM is to determine whether or not, “Are the use of
antibiotics an effective treatment for relieving symptoms of depression in adults?”
METHODS
Specific search criteria were used in the selection of three studies. The population of the
studies used for this review included adults of both sexes between the ages of 20-60 years. One
study worked with patients previously diagnosed with depression, while the remaining studies
selected subjects with no psychiatric, neurological disorders, nor personal or family history of
depression. This selection was made to test beneficial effects of probiotics without the
confounding factors present with ongoing depressive symptomatology.9 In all the studies,
interventions given to the experimental groups consisted of oral multispecies probiotic
supplements of different formulations, containing any of the following species: A. casei, L. casei
L. acidophilus, L. rhamnosus, L. bulgaricus, L. brevis, L.lactis, L. salivarius, L. helveticus, B.
breve, B. bifidum, B. longum, , B. lactis, S. thermophiles. Control groups were given a visuallymatched placebo. Self-reported questionnaires were given to both groups before and after
implementation of interventions to assess improvements in symptoms of depression. All studies
utilized a randomized blind control trial study design to assess outcomes.
The author, using the key words “depression” and “probiotics” carried out a detailed
search using PubMed-NCBI. Each of the articles were published in English and featured in peerreviewed journals. Each of the articles were selected based on relevance to the clinical question
and if it included measurable patient-oriented outcomes (POEMS). Inclusion criteria consisted of
articles that involved randomized controlled trials published between 2010 and 2016. Studies
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excluded were those that included study subjects aged above or below the desired age range of
20-60 years. The statistics reported in these three studies included a mean change from baseline,
p-values, pair samples t-test, non-parametric MWT, Wilcoxon test (WT) and ANOVA. Table 1
displays the demographics and characteristics of these three studies.
Table 1: Demographics & Characteristics of included studies
Study

Type

#Pts

Age
(yrs)

Inclusion Criteria

Exclusion Criteria

W/D

Interventio
ns

Akkasheh10
(2016)

RCT

40

20-55

Patients with MDD based
on DSM-IV criteria with a
score of ±15 on the
Hamilton Depression
Rating Scale

Age <20 y or >55 y with a
history of coronary
infarction, angina pectoris,
pregnancy or lactation, or
substance abuse; and taking
dietary supplements or
probiotic supplements during
the previous two months

5

Probiotic
Capsule
QD x 8
weeks (56
days)

Messaoudi7
(2011)

RCT

57

30-60

A score of £ 12 on the
HADS-anxiety subscale
(HADS-A) and the HADSdepression subscale
(HADS-D) and a score of £
20 on the HADS total score
on initial examination.

Neurological, psychiatric,
renal, hepatic, CVD and
respiratory diseases, food
allergy, taking psychotropic
drugs, nutritional
supplements, melatonin,
anxiolytics, antidepressants,
narcotics, hormones, > 5
cups of coffee or tea/d, 0.2
liters of cola, 30–40 g of
chocolate, three glasses of
wine, or two fermented dairy
products, smoking more than
20 cigarettes.

2

Probiotic
Powder
Formulatio
n QD x 30
days

1

Probiotic
FoodSupplemen
t Powder
QD x 28
days

Pregnant women and
subjects in another clinical
study over the past two
months.
Steenberge
n9(2015)

RCT

40

Mean
age of
20

Non-smokers with no
cardiac, renal, hepatic
conditions, allergies,
intolerance to lactose,
gluten, prescribed
medication, drug use, and
no > 3–5 alcohol
units/week.
No psychiatric,
neurological disorders, no
personal or family history
of depression or migraines

All subjects that did not meet
the inclusion criteria.
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OUTCOMES MEASURED
Each outcome measured was a POEM and was measured using self-reported
questionnaire assessment tools. Questionnaire responses were totaled and scored for each
participant. Changes in mean total scores before and after probiotic intervention were used to
help generative conclusions. Each article used different questionnaire assessment tools. The first
study by Akkasheh et al. measured the effects of probiotic intake on symptoms of depression
using the Beck Depression Inventory (BDI). BDI is a self-compiled questionnaire of 21 items in
multiple-choice format.1 On each item there are four statements and the subjects were instructed
to choose the one that best described their situation. The participant responses were given the
scores 0, 1, 2, and 3, with 0 for the normal or least depressive statement and 3 for the most
depressive statement. Total BDI scores were calculated by adding together the scores of each
item. Scores range from 0 to 63 (0-13: minimal depression, 14-19: mild depression, 20-28:
moderate depression and 29-63: severe depression).9
The second study by Messaoudi et al. used the Hopkins Symptom Checklist-90 (HSCL90) and the Hospital Anxiety and Depression Scale (HADS) to address the potential anxiolytic
effects of probiotic formulations on human distress, anxiety and depression. The HSCL-90 is a
90-item self-reported multidimensional questionnaire, screening for a broad range of
psychopathological disorders. It measures nine primary symptom dimensions (somatization,
obsessive–compulsive, interpersonal sensitivity, depression, anxiety, anger–hostility, phobic
anxiety, paranoid ideation and psychoticism).7 Each item was rated on a five-point scale, ranging
from ‘not at all’ to ‘extremely’. The HSCL-90 subscale focused on in this review is depression.
The HADS is a fourteen-item, four-point scale, self-assessment that ranges from 0 (never) to 4
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(very often). It is often applied and convenient for measuring psychological distress in subjects
with somatic or psychosomatic disorders.2 Three sub-scores were obtained: HADS global,
HADS-A (anxiety subscale) and HADS-D (depression subscale). The HADS-D is the main
subscale of interest for this review.
And lastly, the third article by Steenbergen et al. measured the effects of multispecies
probiotic intervention on cognitive reactivity to sad mood using the revised Leiden Index of
Depression Sensitivity Scale (LEIDS-r) and the Beck Depression Inventory II (BDI- II). The
LEIDS-r is a self-report questionnaire with 34 items that assesses to what extent dysfunctional
thoughts are activated when experiencing mild dysphoria (i.e., it measures cognitive reactivity to
sad mood, also referred to as vulnerability to depression).9 The scale used in the study consisted
of 6 subscales that measure vulnerability and a total of 136 points could be obtained from the
summation of each subscale score. The BDI-II is very similar to BDI, but revised to identify
symptoms of severe depression and has been found to be a valid indicator of depression.9
RESULTS
The study by Akkasheh et al. included 40 patients diagnosed with MDD, according to
DSM-IV criteria, of both sexes, ranging in age from 20 to 55 years old. Only 35 people
completed the trial resulting in 17 subjects in the probiotic experimental group and 18 subjects in
the placebo-control group. The probiotic group received one probiotic capsule daily for eight
weeks consisting of three viable and freeze-dried strains of bacteria: Lactobacillus acidophilus (2
x 109 CFU/g), Lactobacillus casei (2 x 109 CFU/g) and Bifidobacterium bifidum (2 x 109
CFU/g). Subjects in the placebo group only received starch capsules with no bacterial strains.
Patients were urged to retain normal routines before treatment to prevent confounding variables.
Both study groups showed improvement in BDI scores with a decrease in mean values from
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baseline, as seen in table 2. The placebo group had a mean change of 1.5, which was
significantly smaller than that of the probiotic group with a mean change of 5.7. Statistical
analysis based on pair-samples t-test found the group means to be statistically significant with a
p-value well below 0.05 at 0.001.
Table 2: Mean change from baseline ± SDs, Akkasheh et al.10
BDI total score
Probiotic Supplementation
-5.7 ± 6.4
Placebo
-1.5 ± 4.8
p= .001
The Messaoudi et al. study population included 57 healthy men and women aged 30-60.
On initial evaluation, participants had to have a score of less than or equal to 12 on the HADS-A
and the HADS-D subscale as well as a score of less than or equal to 20 on the HADS global
subscale to participate in the clinical trial. Two subjects were discarded from the study due to
unsatisfactory participation. Subjects were divided into the probiotic formulation (PF, n= 26) and
the placebo (PL, n= 29) group. Once a day for 30 days the PF group consumed a probiotic
combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. In
comparison, the PL group consumed a placebo formulation containing: xylitol, maltodextrin,
plum flavor and malic acid. When the groups were analyzed using the Mann-Whitney U test
(MWT), the percentage change in HSCL-90 Depression scores were considered significant with
a p-value of less than 0.05, as shown in table 3. The median change from baseline was 50% in
the PF group as opposed to only 25% in the PL group. For the HADS-D scores, the median
change from baseline was 31.7% in the PF group as opposed to only 16.7% in the PL group.
Group comparisons for HADS-D scores were not considered to be statistically significant.
However, the change in baseline median HADS-D score values for the PF group compared to
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values at follow-up were statistically significant, with a p-value of 0.008 generated by the
Wilcoxon test.
Table 3: Median Percentage Change from Baseline in HSCL-90 Depression and HADS-D
Score Values, Messaoudi et al.7
HSCL-90 Depression
HADS-D
Probiotic formulation (PF) 50%*
31.7%
Placebo (PL)
25%*
16.7%
*p< .05
The last study by Steenbergen et al. included a group of 40 healthy adults without any
current mood disorders with a mean age of 20. Participants were divided evenly into two groups,
the experimental group received a probiotic food supplement and the control group was given an
inert placebo. The probiotic food supplement came as a sachet containing a freeze-dried powder
of a probiotic mixture containing the following bacterial strains: Bifidobacterium bifidum W23,
Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, L. casei
W56, Lactobacillus salivarius W24, and Lactococcus lactis (W19 and W58). The visually
matched placebo contained a freeze-dried powder consisting of maize, starch and maltodextrins.
Participants were instructed to consume one sachet of their assigned mix per day for a total of 28
days. Pre and post-intervention questionnaires were administered and analyzed using analysis of
variance (ANOVA), data shown in table 4. Pre-intervention data was missing for one participant
in the placebo group. For the probiotic supplementation group, the total mean change in LAID-r
scores from baseline to endpoint was 9.4: p < .001 and in the placebo group the total mean
change in scores was 2.4: p = .63. A statistically significant difference was noticed in the
probiotic group but not in the placebo group. Statistical analysis of group differences was not
made, so therefore it is unsure if the increased mean change seen in the probiotic group is
significant in comparison to the placebo group. The total BDI-II scores for the placebo group
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showed no change from baseline to endpoint and for the probiotic group, a total non-significant
change in scores of only 0.65 was observed, p-values were not reported.
Table 4: LEID-r and BDI-II pre and post-intervention scores and standard error of the
mean (shown in parentheses). Steenbergen et al.9
LEID-r Total
BDI-II
Pre
Post
Pre
Post
Probiotics
42.75 (3.24)* 33.35 (3.51)* 7.90 (1.00)
7.25 (1.19)
Placebo
44.70 (3.24)
42.30 (3.51)
9.10 (1.00)
9.10 (1.19)
*p< .001
DISCUSSION
The probiotic interventions used in the studies discussed in this review were found to
have a positive effect on symptoms of depression, indicated by the significant overall decrease in
depression scores during post intervention evaluations. Also, differences between probiotic and
placebo groups were found to be statistically significant in two out of the three studies. Study
participants who were given probiotics had lower depression scores than those who were given
the placebo. This could not be concluded in the Steenbergen et al. study due to lack of analysis.
It is still a common public misconception that all bacteria are harmful. Many are unaware
of the beneficial effects of probiotics, commonly referred to as “good bacteria.” The human body
is heavily dependent on bacterial organisms for digestive and immune health. Preliminary
research, such as the studies presented in this review, are demonstrating that the effects of
probiotics can go even further, with data supporting use in mental health illness and neurological
disorders.7 However, the U.S Food and Drug Administration (FDA) has yet to approve the use of
probiotics for treatment of any medical conditions.11 Probiotics are currently sold over-thecounter as a dietary supplement. Products do not need FDA approval to be dispensed or
marketed. The two most common bacterial groups found in probiotics are lactobacillus and
bifibobacterium. These bacteria are similar to those naturally found in our bodies and therefore
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have low harm risk.11 Use of probiotics are contraindicated in immunocompromised patients,
those with severe acute pancreatitis or damage to the GI tract.12 Generally, probiotics are well
tolerated with few adverse side effects. In comparison probiotics are a much safer option than
antidepressants, which are known to cause unpleasant side effects such as weight gain, sexual
dysfunction, drowsiness, seizures and GI distress. But worst of all, antidepressants are frequently
involved in suicidal ingestion and responsible for a large percentage of drug-related deaths.12
Probiotics can be found in all drugs stores and are relatively inexpensive. The accessibility and
affordability of probiotics are advantages to care not offered by cognitive behavioral therapy.
The shortage of mental health professionals and the high cost of psychiatric care proves to be a
significant barrier to treatment for many with depression.7 Even though insurance companies are
mandated under the Affordable Care Act to cover mental health services as preventative care,
many insured have limited coverage or are unable to manage the associated high copays.
Probiotics have the potential to be useful in the treatment of depression without the adverse side
effects of antidepressant medications and are more cost-effective than psychotherapy.
The potential efficacy of probiotics in the treatment of depression is challenged due to
study limitations. Two key limitations of all three studies were sample size and the lack of
diversity among the sample population. The sample populations were fairly small and consisted
primarily of Caucasians and women. The generalizability of study results to the general public is
limited because effects were seen in such a small number of people and treatment benefits in
men and diverse groups were largely untested. The study by Akkasheh et al. is the only study
that assessed the use of probiotics in patients clinically diagnosed with depression, whereas the
other two studies assessed effects on healthy adults with self-reported symptoms of depression.
The outcomes seen in healthy adults lacks transferability to clinically depressed patients, who
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may respond differently to probiotic administration. The accuracy of these studies come into
question because outcomes were measured primarily based off of self-reported questionnaires.
There is no reliable way to tell if participants gave accurate responses. Using a more concrete
measure such as biochemical markers for depression would help to validate results. Lastly, none
of the studies included dietary measures or controls. They did not track the dietary intake of
participants during the intervention. Possible consumption of probiotic substances such as
fermented foods could have indirectly affected the results of the study and ultimately questions
the reliability of results.
CONCLUSION
The three randomized controlled trials discussed in this review showed improvement in
symptoms of depression after the administration of probiotic supplementation, supporting
probiotics as an effective treatment for relieving symptoms of depression in adults. Probiotics
should be considered as an alternative monotherapy or an additional supplemental treatment
option for people with depression. The possibility of probiotic use in depression offers a safer
and more affordable option in comparison to currently available therapies.
Future studies evaluating the effectiveness of probiotics in depression should use larger
more diverse sample populations to improve generalizability of results. Focused studies on
patients clinically diagnosed with depression can better predict treatment effect and further
quantify the benefits of probiotic use. These data along with research comparing probiotics to
current treatment methods would help to determine whether probiotics should function as
monotherapy or as adjunctive treatment. Considering the limitations of the studies presented,
going forward greater care should be taken to control for confounding variables such as diet and
more reliable measures should be utilized to ensure the accuracy of results.
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